<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="52746">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02419521</url>
  </required_header>
  <id_info>
    <org_study_id>Version 2.0 - 23Mar2015</org_study_id>
    <nct_id>NCT02419521</nct_id>
  </id_info>
  <brief_title>Medtronic Resolute Onyx Core (2.25 mm - 4.0 mm) Clinical Study</brief_title>
  <official_title>A Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting Stent System Medtronic Resolute Onyx Core (2.25 mm - 4.0 mm) Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Vascular</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Vascular</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the safety and efficacy of the Resolute Onyx
      Zotarolimus-Eluting Coronary Stent System for the treatment of de novo lesions in native
      coronary arteries with a reference vessel diameter of 2.25 mm to 4.2 mm.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-stent Late Lumen Loss as measured by quantitative coronary angiography</measure>
    <time_frame>8 Months</time_frame>
    <description>In-stent late lumen loss at 8-months post-procedure as measured by quantitative coronary angiography</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cardiac Death</measure>
    <time_frame>8 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Myocardial Infarction (TVMI)</measure>
    <time_frame>8 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Revascularization (TLR)</measure>
    <time_frame>8 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major Adverse Cardiac Event (MACE)</measure>
    <time_frame>8 Months</time_frame>
    <description>Defined as death, myocardial infarction (Q wave and non-Q wave), emergent coronary bypass surgery, or clinically-driven repeat target lesion revascularization by percutaneous or surgical methods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Lesion Failure (TLF)</measure>
    <time_frame>8 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target Vessel Failure (TVF)</measure>
    <time_frame>8 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent Thrombosis (ST)</measure>
    <time_frame>8 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Device</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Medtronic Resolute Onyx Zotarolimus-Eluting Stent System Core (2.25 mm - 4.0 mm)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Resolute Onyx Stent - 2.25 mm - 4.0 mm</intervention_name>
    <arm_group_label>Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must be an acceptable candidate for percutaneous coronary intervention (PCI),
             stenting, and emergent coronary artery bypass graft (CABG) surgery

          -  Must have clinical evidence of ischemic heart disease, stable or unstable angina,
             and/or a positive functional study

          -  Must require treatment of either a) a single target lesion amenable to treatment OR
             b) two target lesions located in separate target vessels

          -  Target lesion(s) must be de novo lesion(s) in native coronary artery(ies)

        Exclusion Criteria:

          -  Known hypersensitivity or contraindication to aspirin, heparin and bivalirudin,
             thienopyridines, cobalt, nickel, platinum, iridium, chromium, molybdenum, polymer
             coatings (e.g. BioLinx) or a sensitivity to contrast media, which cannot be
             adequately pre-medicated

          -  History of an allergic reaction or significant sensitivity to drugs such as
             zotarolimus, rapamycin, tacrolimus, everolimus, or any other analogue or derivative

          -  History of a stroke or transient ischemic attack (TIA) within the prior 6 months

          -  Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months

          -  History of bleeding diathesis or coagulopathy or will refuse blood transfusions

          -  Concurrent medical condition with a life expectancy of less than 12 months

          -  Currently participating in an investigational drug or another device trial that has
             not completed the primary endpoint

          -  Documented left ventricular ejection fraction (LVEF) &lt; 30% at the most recent
             evaluation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthew J. Price, MD, FACC, FSCAI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Scripps Green Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morton Plant Hospital</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint John's Hospital</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Vincent Heart Center of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barnes Jewish University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mount Sinai Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Francis Hospital</name>
      <address>
        <city>Roslyn</city>
        <state>New York</state>
        <zip>11576</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanford Medical Center</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Elyria Medical Center</name>
      <address>
        <city>Elyria</city>
        <state>Ohio</state>
        <zip>44035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Medical Center</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AnMed Health Medical Center</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centennial Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dallas VA Medical Center</name>
      <address>
        <city>DAllas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <lastchanged_date>October 6, 2016</lastchanged_date>
  <firstreceived_date>April 14, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
